4.5 Review

Pharmacogenetics of antiretroviral therapy

Journal

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 10, Issue 8, Pages 1119-1130

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2014.930128

Keywords

abacavir; antiretrovirals; HIV; pharmacogenetics; pharmacogenomics; tenofovir

Funding

  1. Fundacion Investigacion y Educacion en SIDA (FIES)
  2. European Community's Seventh Framework Programs NEAT (European AIDS Treatment Network) [LSHM-CT-2006-037570]
  3. CHAIN (Collaborative HIV and Anti-HIV Drug Resistance Network) [FP7/2007-2013-223131]
  4. Red de Investigacion en SIDA [ISCIII-RETIC-RD12/0017/0031]

Ask authors/readers for more resources

Introduction: Human genetic testing is rapidly entering into most medical disciplines, mainly as a way to predict hereditary conditions including predisposition to cancers or degenerative diseases. Another area of interest for human genomics is to ascertain the therapeutic effect and prevent potential toxicities and/or drug-drug interactions of medication. Areas covered: Several human genotypes have been associated with differences in the metabolism and transport of antiretroviral agents that ultimately affect drug exposure. The accelerated discovery of new gene mutations and polymorphisms that influence the effects of antiretroviral drugs provides a unique opportunity for a personalized medicine approach in the management of lifelong HIV therapy. Expert opinion: Integration of human genomic screening into HIV clinical management will be cost-effective, maximizing the benefit of drugs with the lowest risk of side effects for a given patient.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available